Synergy between PPARγ Ligands and Platinum-Based Drugs in Cancer
- 8 May 2007
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 11 (5), 395-406
- https://doi.org/10.1016/j.ccr.2007.02.025
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Rosiglitazone ameliorates cisplatin-induced renal injury in miceNephrology Dialysis Transplantation, 2006
- A Novel Peroxisome Proliferator-activated Receptor γ Isoform with Dominant Negative Activity Generated by Alternative SplicingJournal of Biological Chemistry, 2005
- Hic-5 regulates an epithelial program mediated by PPARγGenes & Development, 2005
- AP-1: a double-edged sword in tumorigenesisNature Reviews Cancer, 2003
- A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal CancerThe Cancer Journal, 2002
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- The Mechanism of Action of Cisplatin: From Adducts to ApoptosisPublished by Wiley ,1999
- Cellular and molecular determinants of cisplatin resistanceEuropean Journal Of Cancer, 1998
- PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2AGenes & Development, 1997
- Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factorCell, 1994